Skip to content
Try Mental Wellness – Lifestyle
Author:
BeyondSpring, Inc.
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
September 30, 2026
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
August 14, 2026
BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value
June 4, 2026
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
June 2, 2026
BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting
May 18, 2026
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
April 22, 2026